News
Vamousse® head lice treatment now distributed by Walgreens in the USA
08 April 2015
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products, is pleased to announce that it has secured a listing for its Vamousse Treatment product with Walgreens in the USA.
Walgreens
Through the merger of Walgreens and Alliance Boots completed in December 2014, Walgreens Boots Alliance is now the first global pharmacy-led, health and wellbeing enterprise in the world. In the USA, Walgreens is the largest pharmacy chain with more than 8,000 stores. The Walgreens listing, which follows the recent announcement of the Vamousse listing with CVS as well as with the top three pharmaceutical distributors in the USA, represents an additional key milestone for the roll-out of TyraTech's Vamousse products in the USA. It is expected that the Vamousse Treatment product will be available in the majority of Walgreens stores nationwide in the USA from May 2015.
Bruno Jactel, Chief Executive Officer, said: "The Walgreens listing, following the recent CVS listing and the listing with Walmart last year will put our Vamousse head lice treatment in three of the top four pharmacy retailers in the USA. This is a significant step in the implementation of our strategy of making our products widely available to customers and building a national brand in the US. The TyraTech team is committed, more than ever, to building a brand, expanding distribution for our Vamousse products and creating value for our shareholders.
Further information on Vamousse® is available on the Company's website at http://www.vamousselice.com/
For further information please contact:
| TyraTech Inc. Bruno Jactel, Chief Executive Officer Vincent Morgus, Chief Financial Officer and Treasurer |
Tel: +1 919 415 4340 Tel: +1 919 415 4287 |
| SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady |
Tel: +44 203 368 3551 Tel: +44 203 368 3552 |
| Allenby Capital Limited , Joint Broker Chris Crawford |
Tel: +44 20 3328 5656 |
| Whitman Howard Limited, Joint Broker Ranald McGregor-Smith/ Niall Devins |
Tel: +44 20 7659 1240 |
| Walbrook, Financial PR and IR Nick Rome/ Guy McDougall |
Tel: +44 20 7933 8790 |
Disclaimer for U.S. Site Visitors
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.